Moderna misses on earnings as costs rise from surplus production capacity, lower demand for Covid shotsCNBC • 02/23/23
Moderna earnings fall short of estimates amid steep decline in COVID vaccine sales, expects to file for approval of RSV vaccine in first halfMarket Watch • 02/23/23
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdatesAccesswire • 02/23/23
Moderna Pops After FDA Grants Its Cancer Vaccine A Breakthrough DesignationInvestors Business Daily • 02/22/23
Moderna stock pops after receiving cancer-vaccine candidate gets FDA breakthrough designationMarket Watch • 02/22/23
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk MelaAccesswire • 02/22/23
Moderna Hopes To Build On mRNA Tech Used In Its Covid Shots—By Targeting Genetic DiseasesForbes • 02/22/23
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing TherapiesAccesswire • 02/22/23
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)Accesswire • 02/17/23
Moderna's stock hit as flu-vaccine trial fails on one target. Meanwhile, China declares victory over COVID.Market Watch • 02/17/23
Moderna Hypes 'Important Step' In Flu Shot Results, But Market DisagreesInvestors Business Daily • 02/17/23
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine CandidateAccesswire • 02/16/23
The 10 Biggest Companies Reporting Earnings in the Fourth Week of February 202324/7 Wall Street • 02/16/23